Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BGF MDI HFO versus BGF MDI HFA crossover equivalence study in COPD
2023-506565-57-00Phase 3Completed
- Sponsor
- AstraZeneca
- Start
- Mar 2024
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 14
01
Overview
Phase 3, randomised, double-blind trial of budesonide, glycopyrronium and formoterol in chronic obstructive pulmonary disease (COPD) (3 arms), sponsored by AstraZeneca. Primary endpoints: Equivalence on change from baseline in FEV1 AUC(0-4), Equivalence on change from baseline in morning pre-dose trough FEV1 and 2 more. Started Mar 2024; status: completed.
02
Drugs
budesonideglycopyrroniumformoterol
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on 2023-506565-57-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-506565-57-00.